Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021;11(1):93-105.
doi: 10.3233/JPD-202302.

Genetics of Progressive Supranuclear Palsy: A Review

Yafei Wen  1 , Yafang Zhou  2 , Bin Jiao  1   3   4 , Lu Shen  1   3   4   5
Affiliations
Review

Genetics of Progressive Supranuclear Palsy: A Review

Yafei Wen et al. J Parkinsons Dis. 2021.

Abstract

Progressive supranuclear palsy (PSP) is an atypical parkinsonism with prominent 4R-tau neuropathology, and the classical clinical phenotype is characterized by vertical supranuclear gaze palsy, unprovoked falls, akinetic-rigid syndrome and cognitive decline. Though PSP is generally regarded as sporadic, there is increasing evidence suggesting that a series of common and rare genetic variants impact on sporadic and familial forms of PSP. To date, more than 10 genes have been reported to show a potential association with PSP. Among these genes, the microtubule-associated protein tau (MAPT) is the risk locus with the strongest effect size on sporadic PSP in the case-control genome-wide association studies (GWAS). Additionally, MAPT mutations are the most common cause of familial PSP while the leucine-rich repeat kinase 2 (LRRK2) is a rare monogenic cause of PSP, and several other gene mutations may mimic the PSP phenotype, like the dynactin subunit 1 (DCTN1). In total, 15 MAPT mutations have been identified in cases with PSP, and the mean age at onset is much earlier than in cases carrying LRRK2 or DCTN1 mutations. GWAS have further identified several risk loci of PSP, proposing molecular pathways related to PSP. The present review focused on genetic studies on PSP and summarized genetic factors of PSP, which may help to elucidate the underlying pathogenesis and provide new perspectives for therapeutic strategies.

Keywords: Progressive supranuclear palsy; genetics; genome-wide association study; haplotype; microtubule-associated protein tau; mutations; variants.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to report.

Figures

Fig. 1
Fig. 1
Six isoforms of protein tau and 15 mutations of MAPT associated with PSP.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kawashima M, Miyake M, Kusumi M, Adachi Y, Nakashima K (2004) Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord 19, 1239–1240. - PubMed
    1. Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU (2017) Advances in progressive supranuclear palsy: New diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16, 552–563. - PMC - PubMed
    1. Ling H (2016) Clinical approach to progressive supranuclear palsy. J Mov Disord 9, 3–13. - PMC - PubMed
    1. Armstrong MJ (2018) Progressive supranuclear palsy: An update. Curr Neurol Neurosci Rep 18, 12. - PubMed
    1. Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10, 333–359. - PubMed

Publication types

MeSH terms